CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology, Inc. Common stock

CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).

Whitesun Healthcare Ventures

WI Harper Group

Song Hong Fang

Ally Bridge Group

ORI Capital

Perseverance Capital Management

Camford Capital

Kissei Pharmaceutical

Decheng Capital

RA Capital Management

Sirona Capital

Acorn Bioventures

Longitude Capital

Malin Corporation

Foresite Capital

BVF Partners

TCG Crossover

Avidity Partners

Janus Henderson Investors

CG Oncology

Join Dr. Vijay Kasturi, CG Oncology’s Chief Medical Officer, at the 2024 American Urological Association (AUA) Annual Meeting in #SanAntonioTX. Dr. Kasturi will share how CG Oncology is advancing the fight against bladder cancer with innovative solutions at our booth #100 from May 3-5 at 12:30 pm CDT. He will provide insights into our pipeline, clinical trials, and the potential of cretostimogene grenadenorepvec as a therapeutic option.

📅 May 3-5, Booth #100
⏰ 12:30 pm (10 to 15 mins) 

Our team is looking forward to sharing our latest advancements for #NMIBC patients.

👉 More on the event here: auanet.org/AUA2024

#CGOncology #BladderCancer #UroOncology #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #TherapeuticAdvances #AUA24

Each year, more than 80,000 people in the United States receive a #bladdercancer diagnosis. 🩺

CG Oncology is committed to addressing the unmet needs of these patients and focused on developing bladder-saving therapeutics. Join us in the Bladder Cancer Advocacy Network (BCAN) 2024 Walks to End Bladder Cancer, happening all across the country. These walks are a celebration of hope as we unite to advance research and provide support for patients and their loved ones. 

👉 Find a walk near you at https://bit.ly/3x65qD3 

#CGOncology #EndBladderCancer #BladderCancerAwareness #BladderCancer #UroOncology #CancerResearch #MedicalResearch #CancerSupport #BCANWalk2024 

CG Oncology is excited to share our updated results on cretostimogene grenadenorepvec at the 2024 American Urological Association (AUA) Annual Meeting in San Antonio, TX from May 3-6, 2024.  

Dr. Robert Svatek of UT Health San Antonio and Dr. Mark Tyson, M.D., M.P.H of Mayo Clinic Scottsdale, AZ, will present abstracts highlighting cretostimogene, while an oral presentation will feature the interim 12-month Phase 3 data from the BOND-003 trial. If you are attending #AUA2024, we invite you to join us and meet our team at booth #100. Cretostimogene has the potential to be a backbone therapy for patients diagnosed with bladder cancer. 

📖 For more information, read the full release: https://bit.ly/3PEUbI0 

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

🧬 Excitement is building for #AUA2024! Join us at the 2024 American Urological Association (AUA) Annual Meeting, taking place in #SanAntonioTX from May 3-6.

Meet CG Oncology’s Medical Team at Booth #100 and explore the MoA of cretostimogene grenadenorepvec through Virtual Reality. This is an incredible opportunity to gain insights into the future of #bladdercancer therapy and learn how our pipeline and clinical trial programs can complement your practice. More details coming soon!

🗓️ Learn more here: auanet.org/AUA2024

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

CG Oncology is growing! We recently welcomed some exceptionally talented team members who will be joining with us in Attacking Bladder Cancer for a Better Tomorrow™. Welcome to CG Oncology Adrian Knoth, M.Sc, PMP, Anthony Fernandez, PharmD, MSL-BC, Davis Bauman, Shelja Patel, PharmD, RPh, BCMAS and Victoria D'Anthony. If you are interested in joining our team of intelligent and passionate team members that share our Vision, Mission and Values, please visit our Careers Page: https://lnkd.in/e-UiUYdg

Today marks another step forward in our ongoing effort to transform the treatment landscape for #bladdercancer. The first patient has been dosed in the PIVOT-006 Phase 3 trial, which is investigating cretostimogene grenadenorepvec as an investigational drug for the treatment of Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (#NMIBC) following transurethral resection of the bladder tumor (#TURBT).  

With over 80,000 individuals diagnosed annually with bladder cancer in the United States, the PIVOT-006 study addresses the unmet medical need for patients facing limited treatment options. Dr. Neal Shore, MD, FACS of Carolina Urologic Research Center confirmed the potential impact of this therapy: “Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer.”
 
Learn more about the PIVOT-006 study and how CG Oncology is committed to developing novel bladder-sparing therapeutics that improve patient outcomes.

📄 Read the full release: https://bit.ly/49AOqTO 
 
#Urology #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #PatientCare #Immunotherapy #Therapeutics #CGOncology #PIVOT006

	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
revenue		194K -		9K -	1K 88.89%	529K 52,800%	111K 79.02%
cost of revenue	4K -	7.84M 195,950%	4K 99.95%		4K -	4K 0%	7K 75%
gross profit	-4K -	-7.65M 191,100%	-4K 99.95%	9K 325%	-3K 133.33%	525K 17,600%	104K 80.19%
selling and marketing expenses	-4K -				-4K -	-4K 0%
general and administrative expenses	1.66M -	2.07M 25.11%		2.31M -	3.02M 30.37%	5.79M 91.78%
selling general and administrative expenses	1.65M -	2.07M 25.41%	2.49M 20.12%	2.31M 7.03%	3.01M 30.19%	5.78M 91.90%	7.49M 29.44%
research and development expenses	7.66M -	7.84M 2.40%	9.83M 25.38%	12.16M 23.68%	15.91M 30.88%	17.21M 8.14%	18.47M 7.32%
other expenses	13K -	8K 38.46%		-8K -	-4K 50%	-9K 125%
cost and expenses	9.31M -	9.91M 6.44%	12.33M 24.32%	14.47M 17.43%	18.93M 30.80%	23.00M 21.47%	25.96M 12.90%
operating expenses	9.31M -	9.91M 6.49%	12.32M 24.28%	14.47M 17.47%	18.93M 30.77%	22.99M 21.47%	25.96M 12.89%
interest expense
ebitda	-9.31M -	-9.72M 4.36%	-12.32M 26.81%	-14.46M 17.36%	-18.93M 30.89%	-22.46M 18.69%	-25.85M 15.05%
operating income	-9.31M -	-9.72M 4.36%	-12.33M 26.80%	-14.47M 17.36%	-18.93M 30.87%	-22.47M 18.68%	-25.85M 15.06%
depreciation and amortization	4K -	4K 0%	4K 0%	5K 25%	4K 20%	4K 0%	7K 75%
total other income expenses net	923K -	8K 99.13%	713K 8,812.50%	-8K 101.12%	2.82M 35,300%	5.54M 96.63%	6.95M 25.54%
income before tax	-8.39M -	-8.67M 3.28%	-11.61M 33.99%	-12.21M 5.11%	-16.12M 32.02%	-16.93M 5.06%	-18.90M 11.63%
income tax expense		-1.05M -		-2.27M -
net income	-8.39M -	-8.67M 3.28%	-11.61M 33.99%	-12.21M 5.11%	-16.12M 32.02%	-16.93M 5.06%	-18.90M 11.63%
weighted average shs out	66.64M -	4.33M 93.50%	66.64M 1,438.61%		66.64M -	47.06M 29.37%	66.66M 41.63%
weighted average shs out dil	66.64M -	4.33M 93.50%	66.64M 1,438.61%		66.64M -	47.06M 29.37%	66.66M 41.63%
eps	-0.13 -	-2 1,438.46%	-0.17 91.50%		-0.24 -	-0.36 50%	-0.28 22.22%
epsdiluted	-0.13 -	-2 1,438.46%	-0.17 91.50%		-0.24 -	-0.36 50%	-0.28 22.22%

CGON

COM:CGONCOLOGY

CG Oncology

Last Close

36.68

30/08 20:00

Market Cap

2.47B

Beta: -

Volume Today

544.38K

Avg: -

Preview